ReviewJournal of clinical laboratory analysis2022
Research progress of gut microbiota in hepatocellular carcinoma.
Review in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Polysaccharides-gut microbiota interaction: mechanisms regulating the hepatocellular carcinoma immune microenvironment.Frontiers in immunology · 2026Review
- Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics.Current drug delivery · 2026Article
- From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma.Frontiers in cellular and infection microbiology · 2026Review
- Article
- Causal relationship between gut microbiota and hepatocellular carcinoma: a two-sample Mendelian randomization and case-control study.Discover oncology · 2025Article
- Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies.Probiotics and antimicrobial proteins · 2025Review
- Understanding the role of Hedgehog signaling pathway and gut dysbiosis in fueling liver cancer.Molecular biology reports · 2025Review
- Gut Microbiota and the Gut-liver Axis in Hepatocellular Carcinoma: A Comprehensive Review of Pathogenesis and Therapeutic Strategies.Anti-cancer agents in medicinal chemistry · 2025Review
- Article
- Liver Cancer Etiology: Old Issues and New Perspectives.Current oncology reports · 2024Review
- Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances.European journal of medical research · 2024Review
- Genetic and clinical factors influencing CF-associated liver disease: the impact ofMedicine and pharmacy reports · 2024Article
- Review
- Research progress of gut microbiota in hepatocellular carcinoma.Journal of clinical laboratory analysis · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth leading cause of cancer-related death in the world. A number of challenges remain for the early detection and effective treatment of HCC. In recent years, microbiota have been proven to be associated with the development of HCC. Many studies have explored the pathogenesis, diagnostic marker, and therapeutic target potential of microbiota in hepatocellular carcinoma. Therefore, we aimed to introduce the research methods and achievements of gut microbiota in hepatocellular carcinoma and discuss the value of gut microbiota in the pathogenesis, diagnosis, and treatment of hepatocellular carcinoma.
methodsKeywords are used to search relevant articles which were mainly published from 2010 to 2021, and we further selected targeted articles and read the full text.
resultsGut microbiota involved in promoting the formation and development of hepatocellular carcinoma, and differential gut microbiota and microbial metabolites have the potential to be the biomarkers of hepatocellular carcinoma. Purposefully regulated gut microbiota can improve the prognosis of patients, which is expected to be used in hepatocellular carcinoma.
conclusionThe study of gut microbiota in hepatocellular carcinoma is definitely worthy of study. In-depth and elaborate research design is crucial for the study of the mechanism of gut microbiota involved in hepatocellular carcinoma, which can provide new directions and targets for the diagnosis, treatment, and prognosis of hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.